Marianna Ferrara

Research activity per year

If you made any changes in Pure these will be visible here soon.

Fingerprint

Dive into the research topics where Marianna Ferrara is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

9 Article

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
Cortellini, A., Di Maio, M., Nigro, O., Leonetti, A., Cortinovis, D. L., Aerts, J. G. J. V., Guaitoli, G., Barbieri, F., Giusti, R., Ferrara, M. G., Bria, E., D'Argento, E., Grossi, F., Rijavec, E., Guida, A., Berardi, R., Torniai, M., Sforza, V., Genova, C., Mazzoni, F. & 41 others, Garassino, M. C., De Toma, A., Signorelli, D., Gelibter, A., Siringo, M., Marchetti, P., MacErelli, M., Rastelli, F., Chiari, R., Rocco, D., Della Gravara, L., Inno, A., Michele, D. T., Grassadonia, A., Di Marino, P., Mansueto, G., Zoratto, F., Filetti, M., Santini, D., Citarella, F., Russano, M., Cantini, L., Tuzi, A., Bordi, P., Minuti, G., Landi, L., Ricciardi, S., Migliorino, M. R., Passiglia, F., Bironzo, P., Metro, G., Adamo, V., Russo, A., Spinelli, G. P., Banna, G. L., Friedlaender, A., Addeo, A., Cannita, K., Ficorella, C., Porzio, G. & Pinato, D. J., 2021, In: Journal for ImmunoTherapy of Cancer. 9, 4, e002421.
Research output: Contribution to journal › Article › peer-review
Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials
Severi, S., Bongiovanni, A., Ferrara, M., Nicolini, S., Di Mauro, F., Sansovini, M., Lolli, I., Tardelli, E., Cittanti, C., Di Iorio, V., Mezzenga, E., Scarpi, E., Ibrahim, T., Paganelli, G. & Zovato, S., 2021, In: ESMO open. 6, 4
Research output: Contribution to journal › Article › peer-review
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study
Cortellini, A., Cannita, K., Tiseo, M., Cortinovis, D. L., Aerts, J. G. J. V., Baldessari, C., Giusti, R., Ferrara, M. G., D'Argento, E., Grossi, F., Guida, A., Berardi, R., Morabito, A., Genova, C., Antonuzzo, L., Mazzoni, F., De Toma, A., Signorelli, D., Gelibter, A., Targato, G. & 32 others, Rastelli, F., Chiari, R., Rocco, D., Gori, S., De Tursi, M., Mansueto, G., Zoratto, F., Filetti, M., Bracarda, S., Citarella, F., Marco, R., Cantini, L., Nigro, O., Buti, S., Minuti, G., Landi, L., Ricciardi, S., Migliorino, M. R., Natalizio, S., Simona, C., De Filippis, M., Metro, G., Adamo, V., Russo, A., Spinelli, G. P., Di Maio, M., Banna, G. L., Friedlaender, A., Addeo, A., Pinato, D. J., Ficorella, C. & Porzio, G., 2021, In: European Journal of Cancer. 148, p. 24-35 12 p.
Research output: Contribution to journal › Article › peer-review
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy
Buti, S., Bersanelli, M., Perrone, F., Bracarda, S., Di Maio, M., Giusti, R., Nigro, O., Cortinovis, D. L., Aerts, J. G. J. V., Guaitoli, G., Barbieri, F., Ferrara, M. G., Bria, E., Grossi, F., Bareggi, C., Berardi, R., Torniai, M., Cantini, L., Sforza, V., Genova, C. & 41 others, Chiari, R., Rocco, D., Della Gravara, L., Gori, S., De Tursi, M., Di Marino, P., Mansueto, G., Zoratto, F., Filetti, M., Citarella, F., Russano, M., Mazzoni, F., Garassino, M. C., De Toma, A., Signorelli, D., Gelibter, A., Siringo, M., Follador, A., Bisonni, R., Tuzi, A., Minuti, G., Landi, L., Ricciardi, S., Migliorino, M. R., Tabbò, F., Olmetto, E., Metro, G., Adamo, V., Russo, A., Spinelli, G. P., Banna, G. L., Addeo, A., Friedlaender, A., Cannita, K., Porzio, G., Ficorella, C., Carmisciano, L., Pinato, D. J., Mazzaschi, G., Tiseo, M. & Cortellini, A., 2021, In: European Journal of Cancer. 150, p. 224-231 8 p.
Research output: Contribution to journal › Article › peer-review
Rebalancing expression of HMGB1 redox isoforms to counteract muscular dystrophy
Careccia, G., Saclier, M., Tirone, M., Ruggieri, E., Principi, E., Raffaghello, L., Torchio, S., Recchia, D., Canepari, M., Gorzanelli, A., Ferrara, M., Castellani, P., Rubartelli, A., Rovere-Querini, P., Casalgrandi, M., Preti, A., Lorenzetti, I., Bruno, C., Bottinelli, R., Brunelli, S. & 4 others, Previtali, S. C., Bianchi, M. E., Messina, G. & Vénéreau, E., 2021, In: Science Translational Medicine. 13, 596
Research output: Contribution to journal › Article › peer-review

Marianna Ferrara

Fingerprint

Research output

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials

Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy

Rebalancing expression of HMGB1 redox isoforms to counteract muscular dystrophy